Keywords
DUF1220, NBPF, protein domain, human brain evolution, copy number, gene duplication, genome evolution, Olduvai Gorge
DUF1220, NBPF, protein domain, human brain evolution, copy number, gene duplication, genome evolution, Olduvai Gorge
We appreciate the helpful comments of reviewers and have modified our original paper to address specific reviewer suggestions. Specifically we have:
1. Altered the title to now read “Changing the name of the NBPF/DUF1220 domain to the Olduvai domain”.
2. After “propose that, for now, the gene family name should remain NBPF.” we added the following sentence: “It is also worth noting that there is an Olduvai domain that is separate from those encoded by NBPF genes: a single, likely ancestral, copy of the domain is found within the PDE4DIP/myomegalin gene.”
3. Changed PFAM to Pfam
4. (after “our African genesis”.) we added the following sentence. “While we are aware that naming a protein domain after a geographic location is unusual, we believe the name Olduvai is more than a place. Rather it has also come to be thought of as a symbol of the efforts of our species to understand itself.”
5. Added the name Mark Johnston to the Acknowledgments.
To read any peer review reports and author responses for this article, follow the "read" links in the Open Peer Review table.
Protein domains are portable units within proteins that can serve important biological functions. They have been implicated in a broad range of key biological phenomena, including development, disease and evolution1,2. Here we jointly propose a new name for a protein domain of approximately 65 amino acids that has been previously termed NBPF3 or DUF12204. Our two labs independently reported the initial studies of this domain, which is encoded almost entirely within a single gene family. The name Neuroblastoma Breakpoint Family (NBPF) was applied to this gene family when the first identified member of the family was found to be interrupted in an individual with neuroblastoma3,5. Prior to this discovery, the Pfam database had termed the domain DUF1220, denoting it as one of many protein domains of unknown function6. It has been Pfam’s intention to use “DUF” nomenclature to serve only as a temporary placeholder until more appropriate names are proposed based on research findings. We believe that additional studies of this domain, primarily from our laboratories over the past 10 years, have resulted in furthering our understanding of these sequences to the point where proposing a new name for this domain is warranted.
Key findings relevant to assigning a name to the domain are as follows:
1. The domain has been repeatedly linked with human-specific evolution. The haploid human genome is estimated to encode approximately 300 copies of the NBPF/DUF1220 domain, while the copy number for other species is substantially lower: great apes 90–120, monkeys 30–40, and all other mammalian species 1–97,8. The increase in humans (at least 165 additional human copies) represents the largest human lineage-specific copy number increase of any coding region in the genome. These findings, involving the copy number of a protein coding domain, provide strong support for an involvement in human-specific evolution.
2. The domain has been linked with human brain evolution and cognitive function. Over the past 10 years we have published several papers on NBPF/DUF1220 protein domains and the NBPF gene family. These have implicated the copy number of the domain in human brain evolution7,9–11, brain size-related phenotypes7,9–11, brain disorders (autism/schizophrenia/micro- and macrocephaly)9,12–14, and measures of cognitive function13,15. Also, our finding of a robust linear association between NBPF/DUF1220 copy number and brain size across primate species was confirmed by an independent study16.
Given the above research findings, a new name for this protein domain that is related to human-specific evolution would be appropriate. We believe a name that would do this is “Olduvai” (ohl’-du-vi) (when necessary it can be abbreviated as “ODV”). This name refers to Olduvai Gorge, which is located in the rift valley of Eastern Africa. Olduvai has been the site of key paleoanthropological discoveries related to human origins and has been called “the Cradle of Mankind”, and “the Grand Canyon of Human Evolution”17. Deposits at the gorge are estimated to cover a time span from 2.1 million to 15,000 years ago, and the fossil remains that have been identified there are thought to represent more than 60 hominins (members of the human lineage). These findings are believed to constitute the most continuous known record of human evolution over the past 2 million years, and the longest known archaeological record of the development of stone-tool industries. Olduvai Gorge was designated part of a UNESCO World Heritage site in 197918. Just as the protein domain appears to be important to human-specific evolution, so too, Olduvai Gorge has provided key insights into human’s evolutionary origin. We believe both are central to the story of what made us human.
Finally, we have also chosen this name because it reflects an appreciation for the important contributions of the scientists who made major anthropological discoveries in Africa in the early/mid-20th century that stimulated further research into human origins and our African genesis. While we are aware that naming a protein domain after a geographic location is unusual, we believe the name Olduvai is more than a place. Rather it has also come to be thought of as a symbol of the efforts of our species to understand itself.
While we believe that the domain and repeat should now be called “Olduvai”, we also propose that, for now, the gene family name should remain NBPF. It is also worth noting that there is an Olduvai domain that is separate from those encoded by NBPF genes: a single, likely ancestral, copy of the domain is found within the PDE4DIP/myomegalin gene. In summary, the NBPF domain and DUF1220 domain will be termed the Olduvai domain, and the NBPF repeat and DUF1220 repeat will be termed the Olduvai repeat. The primary gene family that encodes these sequences will continue to be called NBPF, and the primary domain subtypes will retain established nomenclature (CON1-3, HLS1-3)8. The three-domain block, composed of HLS1, HLS2 and HLS3 subtypes, that is tandemly repeated within several human NBPF genes and responsible for the great majority of additional human copies of the domain, will be called the Olduvai triplet.
The Olduvai domain hyper-amplification in the human lineage was one of the most extreme and rapid copy number expansions in the human genome, and we look forward to additional studies that may provide further insights into the role this protein domain family plays in human disease and evolution.
JMS is founder of GATC Science, LLC, a biotech company involved in genomic research.
JMS is funded by NIH R01 grant MH108684. FVR is supported by the Foundation Against Cancer – Belgium, the Research Foundation – Flanders (FWO-Vlaanderen), and the Queen Elisabeth Medical Foundation (G.S.K.E.), Belgium.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
The authors thank Jonathon Davis, Veronica Searles Quick, Ilea Heft, Laura Dumas, Mark Johnston, Vanessa Andries and Karl Vandepoele for constructive discussions.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Competing Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Is the topic of the opinion article discussed accurately in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Yes
Are arguments sufficiently supported by evidence from the published literature?
Yes
Are the conclusions drawn balanced and justified on the basis of the presented arguments?
Yes
Competing Interests: No competing interests were disclosed.
Is the topic of the opinion article discussed accurately in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Yes
Are arguments sufficiently supported by evidence from the published literature?
Yes
Are the conclusions drawn balanced and justified on the basis of the presented arguments?
Yes
Competing Interests: No competing interests were disclosed.
Is the topic of the opinion article discussed accurately in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Yes
Are arguments sufficiently supported by evidence from the published literature?
Yes
Are the conclusions drawn balanced and justified on the basis of the presented arguments?
Yes
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 2 (revision) 17 Jul 18 |
read | read | |
Version 1 28 Dec 17 |
read | read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)